# PT-141 (Bremelanotide) FAQ: Trials, Mechanism, Dosing | The Record > PT-141 FAQ: what bremelanotide is, whether it works, how it acts on the brain, the approved indication, and the label dose figures — answered directly and cited to the trials. Direct answers on what bremelanotide is, whether it works, how it acts, what it is approved for, and what the label says about dose — each cited where it states a number. ## Does PT-141 work? In the two identical Phase 3 RECONNECT trials in premenopausal women with HSDD, bremelanotide met both coprimary endpoints versus placebo [3]. The benefit was statistically significant but clinically modest, and a published re-analysis disputes its real-world size [9]. Outside that approved indication, there is no Phase 3 efficacy answer. ## What were the results of the PT-141 clinical trials? RECONNECT (n=1,267) reported an integrated FSFI-desire change of +0.35 (P<.001) and an FSDS-DAO item-13 change of -0.33 (P<.001) versus placebo over 24 weeks [3]. A 52-week open-label extension sustained the effect, with nausea, flushing, and headache the most common adverse events [4]. ## What are the benefits of PT-141? In its approved population — premenopausal women with HSDD — trials documented improved sexual desire and reduced desire-related distress versus placebo; the magnitude was modest [3]. All male and erectile benefits are off-label and investigational, not established [1]. ## How big is the effect of bremelanotide on sexual desire? The integrated Phase 3 effects were small: FSFI-desire +0.35 and FSDS-DAO item-13 -0.33 [3]. A published re-analysis argued these benefits, while statistically significant, are of questionable clinical meaningfulness — that is, possibly too small to be noticed in daily life [9]. ## What is PT-141? PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide and melanocortin (MC3R/MC4R) receptor agonist that acts centrally in the brain on the circuitry of sexual desire [1]. It is FDA-approved for one indication only [6]. ## What is PT-141 peptide? It is a cyclic heptapeptide — a ring of seven amino acids — and an analogue of the natural hormone alpha-MSH [1]. The cyclic structure gives it greater stability than the straight-chain melanocortin peptides it is related to. ## What does the PT-141 peptide do? It activates central melanocortin receptors (chiefly MC4R) in hypothalamic and limbic circuits, engaging dopamine pathways tied to sexual motivation [1]. It does not act on vascular blood flow the way erection drugs do — its action is in the brain [1]. ## What is PT-141 used for? Bremelanotide is FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. Every other use — in men, for erectile dysfunction, in postmenopausal women — is off-label and not covered by that approval. ## Is PT-141 the same as bremelanotide? Yes. PT-141 is the research and development designation; bremelanotide is the international nonproprietary name for the same molecule and the name on its approved label [6]. They are one compound under two names. ## What is bremelanotide? Bremelanotide is the approved-drug name for PT-141: a melanocortin receptor agonist approved as a 1.75 mg subcutaneous as-needed injection for HSDD in premenopausal women [6][11]. It acts on central brain circuits, not on blood vessels [1]. ## How does PT-141 work? It stimulates MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopamine signalling linked to sexual desire [1]. This is a central mechanism, unlike PDE-5 inhibitors, which act on peripheral blood vessels [1]. ## What receptors does PT-141 act on? Primarily the melanocortin 4 receptor (MC4R), and secondarily the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. These are the brain-side members of the five-receptor melanocortin family. ## Does PT-141 work through the brain or through blood flow? Through the brain. It acts centrally on melanocortin receptors in sexual-motivation circuits; it does not act on vascular smooth muscle the way PDE-5 inhibitors do [1]. A human fMRI study confirmed it alters central processing of erotic cues [5]. ## What is a melanocortin receptor agonist? A drug that activates melanocortin receptors (MC1R-MC5R), a family of G-protein-coupled receptors that respond to peptides such as alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes, which is why its effect is on desire rather than blood flow. ## Does PT-141 increase testosterone? No. PT-141 does not act through the HPG axis and does not directly raise testosterone [12]. Its effect on sexual desire runs through central melanocortin signalling — a common misconception worth correcting [1]. ## How is PT-141 different from PDE-5 inhibitors? PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on the brain's sexual-desire circuitry [1]. The two mechanisms are distinct, which is exactly why combination research exists [13]. ## What is the PT-141 dosage? Reported as a finding only: the approved label specifies bremelanotide 1.75 mg subcutaneously as needed, no more than one dose per 24 hours and no more than eight doses per month [11]. This is not a protocol for any reader to follow. ## How much PT-141 should I take? This site does not recommend a dose. It reports trial and label figures: the approved as-needed dose in the studied population was 1.75 mg subcutaneous, with strict frequency limits [11]. Any decision about use belongs with a qualified clinician, not a website. ## How much PT-141 to inject? The approved label figure is 1.75 mg subcutaneous as needed; Phase 2 dose-finding evaluated 0.75, 1.25, and 1.75 mg [8][11]. These are reported as research findings, not as guidance to self-administer. ## What is the PT-141 dosage for women? In the approved premenopausal-HSDD indication, the label dose is bremelanotide 1.75 mg subcutaneous as needed (maximum one per 24 hours, eight per month) [11]. Reported as a label fact, not a recommendation. ## How do you reconstitute PT-141? The approved finished drug is a pre-filled autoinjector and is not reconstituted [11]. Material sold as a "PT-141 research chemical" is a separate, laboratory-only product; this site does not provide reconstitution or self-administration instructions. ## How do you take PT-141? In trials and on the label, bremelanotide is given subcutaneously, as needed, at least 45 minutes before anticipated activity [11]. Early research also used intranasal and intravenous routes; intranasal was discontinued for pharmacokinetic variability [1]. Reported as findings, not instructions. --- A broadsheet reading of the PT-141 (bremelanotide) record — the one approved indication set in banner type, the modest measured effect printed beside the re-analysis that contests it, the nausea-led tolerability cost run in full, and the unverified field reports kept on their own torn dispatch; no clinic behind the masthead and nothing here dosed, dispensed, or sold.